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Abstract
Background: Cardiac remodeling is generally an adverse sign and is associated with heart failure (HF) progression. 
NFkB, an important transcription factor involved in many cell survival pathways, has been implicated in the remodeling 
process, but its role in the heart is still controversial. Recently, a promoter polymorphism associated with a lesser 
activation of the NFKB1 gene was also associated with Dilated Cardiomyopathy. The purpose of this study was to 
evaluate the association of this polymorphism with clinical and functional characteristics of heart failure patients of 
different etiologies.
Methods: A total of 493 patients with HF and 916 individuals from a cohort of individuals from the general population 
were investigated. The NFKB1 -94 insertion/deletion ATTG polymorphism was genotyped by High Resolution Melt 
discrimination. Allele and genotype frequencies were compared between groups. In addition, frequencies or mean 
values of different phenotypes associated with cardiovascular disease were compared between genotype groups. 
Finally, patients were prospectively followed-up for death incidence and genotypes for the polymorphism were 
compared regarding disease onset and mortality incidence in HF patients.
Results: We did not find differences in genotype and allelic frequencies between cases and controls. Interestingly, we 
found an association between the ATTG1/ATTG1 genotype with right ventricle diameter (P = 0.001), left ventricle 
diastolic diameter (P = 0.04), and ejection fraction (EF) (P = 0.016), being the genotype ATTG1/ATTG1 more frequent in 
patients with EF lower than 50% (P = 0.01). Finally, we observed a significantly earlier disease onset in ATTG1/ATTG1 
carriers.
Conclusion: There is no genotype or allelic association between the studied polymorphism and the occurrence of HF 
in the tested population. However, our data suggest that a diminished activation of NFKB1, previously associated with 
the ATTG1/ATTG1 genotype, may act modulating on the onset of disease and, once the individual has HF, the genotype 
may modulate disease severity by increasing cardiac remodeling and function deterioration.
Background
Cardiac remodeling is defined as alterations in left ven-
tricular (LV) chamber mass, geometry and function, and
is associated with heart failure (HF) progression[1].
Remodeling leads to LV dilatation and impaired systolic
function and transcends the anatomical changes in ven-
tricular geometry, leading to ultra-structural cellular
modifications in cardiomyocytes[2,3]. Nuclear factor
(NF) κB is a central integrator of stress response and cell
survival pathways[4]. Its activation is observed in the
myocardial tissue from HF patients of various etiolo-
gies[5] suggesting that inflammatory pathways are oper-
ant in the development of HF[6].
The Rel/NFκB transcription factor is from a family of
evolutionary conserved proteins that are all related
through the highly conserved Rel homology binding
domain. There are five members of the NFκB family in
mammals: p50/p105, p65/RelA, cRel, RelB and p52/
p100[7]. In general, transcription activation is dependent
on subunit's dimerization. In several tissues, including
the heart, the major form of NFκB is the heterodimer
p50/p65[8]. The p50 subunit (50 kDa) is encoded in
humans by the gene NFKB1 and corresponds to the N-
terminus of the cytoplasmic protein p105 (105 kDa)[9].
* Correspondence: alexandre.pereira@incor.usp.br
1 Laboratory of Genetics and Molecular Cardiology, Heart Institute (InCor), Sao 
Paulo University Medical School, Sao Paulo, Brazil
Full list of author information is available at the end of the articleSantos et al. BMC Medical Genetics 2010, 11:89
http://www.biomedcentral.com/1471-2350/11/89
Page 2 of 8
NFκB primarily resides inactive in the cytoplasm by asso-
ciation with IκB. Its activation can be triggered by a vari-
ety of stimuli that ultimately lead to phosphorylation,
ubiquitination and degradation of IκB, releasing NFκB
dimers to nuclear translocation, where NFκB dependent
transcription of a large and diverse array of target genes
can be initiated and various physiological and pathologi-
cal processes modulated [10].
NFKB1 transcription activation is associated with the
development of several diseases such as asthma, inflam-
matory arthritis, septic shock, lung fibrosis, cancer, AIDS,
inflammatory bowel disease, atherosclerosis, diabetes
and stroke[10,11], mainly acting by transcription activa-
tion of inflammatory processes[12], but the role of its
activation in the heart remains controversial. First, NFκB
was believed to act, in general, worsening cardiac remod-
eling or dysfunction mainly through activation of a pro-
inflammatory pathway enhancing HF[13-17]. However,
recently, several studies have found evidence pointing to a
new role for NFκB in the HF scenario. In these studies,
NFκB is thought to play a protective role by acting in an
anti-inflammatory pathway, participating in matrix
remodeling and attenuating oxidative stress thus mitigat-
ing the HF progression [18-21].
Recently, two different in vitro studies observed that an
insertion (ATTG2) of an ATTG sequence at position -94
of the promoter region of the NFKB1 gene increases tran-
scriptional activity compared to the allele with the dele-
tion (ATTG1)[22,23]. In humans, the production of the
p105 and p50 proteins has been shown to be greater
among individuals with the ATTG2/ATTG2  genotype
[23]. The purpose of the present work was to study the
association of this functional polymorphism with differ-
ent phenotypes related to HF through an evaluation of
the clinical characteristics of 493 individuals with HF of
different etiologies.
Methods
Study population
Five-hundred and three (503) patients with heart failure
in functional class III or IV of the New York Heart Asso-
ciation were studied. The patients were included as part
of a secondary-cohort of HF individuals at a tertiary car-
diology care center in Sao Paulo, Brazil (Heart Institute of
the Sao Paulo University Medical School). Ascertainment
period was from August, 2002 to March, 2004.
The diagnosis of heart failure was made according to
previously published criteria [24,25]. The classification of
the etiologies of heart failure followed previous recom-
mendations[25]. As such, the diagnosis of chronic heart
failure was made through both clinical and imaging pro-
cedures when necessary. Ischemic cardiomyopathy diag-
nosis was made when a clear history of previous
myocardial infarction and no other probable cause of
heart dysfunction was present or, alternatively, through
coronary angiography. All patients with the final diagno-
sis of idiopathic dilated cardiomyopathy were studied
through coronary angiography to exclude the possible
diagnosis of ischemic cardiomyopathy. In the present
analysis we have used data from 493 participants.
Follow-up
Beginning of follow-up was defined as enrollment in the
protocol. Follow-up was assessed in the last outpatient
medical visit or by telephone contact. In addition, the
mortality database of São Paulo City Authority was also
scrutinized to discover patient deaths (ProAim--Pro-
grama de Aprimoramento de Informações de Mortali-
dade do Municipio de São Paulo). Last follow-up was
evaluated in April, 2009. Primary end-point studied was
overall mortality.
Control population - General population of Vitória/ES, 
Brazil
A cross-sectional study of risk factors for cardiovascular
diseases was performed in the urban population of Vito-
ria, Brazil, using the WHO-MONICA project guidelines
[26]. The study design was based on cross-sectional
research methodology and was developed by means of
surveying and analyzing socioeconomic and health data
in a probabilistic sample of residents aged 25 to 64 years
from the municipality of Vitoria, ES, Brazil. The popula-
tion was randomized and the sample was socioeconomi-
cally, geographically and demographically representative
of the residents of this municipality. A selection of 2,268
residential homes located in Vitoria was made and these
were visited. The project received approval from the Eth-
ics Committee of the Biomedical Center of Universidade
Federal do Espírito Santo (UFES). The selected individu-
als were asked to attend the Cardiovascular Investigation
Clinic of the University Hospital for tests to be performed
on the following day. Of the total sample, 1,577 individu-
als attended. Participants were submitted to physical
examination. Major cardiovascular risk factors such as
smoking habits, alcohol intake, sedentarism, diabetes and
hypertension were inquired. Blood glucose, total choles-
terol, lipoprotein fractions, and triglycerides were assayed
by standard techniques in a 12-hour fasting blood sam-
ple. In the present analysis we have used data from 916
participants.
Left ventricular function assessment
Left ventricular ejection fraction was determined by M-
mode echocardiography. In some patients two-dimen-
sional method was employed, using Simpson. The evalua-
tion of the left ventricular function was performed by the
echocardiography staff in a blinded way in relation to theSantos et al. BMC Medical Genetics 2010, 11:89
http://www.biomedcentral.com/1471-2350/11/89
Page 3 of 8
genotypes and was conducted according to previously
published recommendations[27].
Genotype determination
Extraction of genomic DNA was performed from leuko-
cytes separated from whole blood using a standard
method[28]. DNA samples were further diluted with PCR
grade water to a concentration of 10 ng/μL. The -94
insertion/deletion polymorphism was detected by a High
Resolution Melt technique. The primer sequences were F
5'-CATGACTCTATCAGCGGCACT-3' and R 5'-
GGCTCTGGCTTCCTAGCAG-3'. Primers were
designed using accession number [GenBank:
AF213884.2] including a region that does not possess
other polymorphisms than the rs28362491 and to be
annealed at 60°C using the Primer3 software. The final
optimal reaction conditions were empirically determined.
The reaction mixture used BioTaq DNA Polymerase (Bio-
Quimica, Brazil) and consisted of 10 ng of genomic DNA,
1× Assay buffer, 2 mM MgCl2, 200 nM of each primer,
200 μM of dNTPs, 1,5 μM of SYTO9 (Invitrogen, Carls-
bad, USA), 0.5 U of BioTaq DNA Polymerase and PCR
grade water in a volume of 10 μL. PCR cycling and HRM
analysis was performed on the Rotor-Gene™ 6000 equip-
m e n t  ( Q i a g e n ,  C o u r t a b o e u f ,  F r a n c e ) .  T h e  P CR  cy c l i n g
conditions were as follows: one cycle of 94°C for 5 min-
utes; 35 cycles of 94°C for 20 seconds, 60° for 20 seconds,
72°C for 20 seconds; and one cycle of 72°C for 5 minutes
and an HRM step from 72 to 94°C rising at 0.1°C per sec-
ond. Curve genotypes were confirmed by an electropho-
resis run on a 4% agarose gel (UltraPure™ - Agarose 1000,
Invitrogen, Carlsbad, USA) stained with ethidium bro-
mide (1 μg/ml). Ten percent of the samples were ran-
domly chosen and re-genotyped and agreement was of
100%.
Statistical analysis
Data are presented as means ± standard deviation (SD)
for continuous variables and as frequencies for categori-
cal variables. Differences in baseline characteristics
among groups were analyzed using ANOVA for continu-
ous variables and the Chi-square test for categorical vari-
ables. Hardy-Weinberg equilibrium was evaluated by a
Chi-square test.
The probability of survival and disease onset was evalu-
ated by the Kaplan Meier method relative to clinical vari-
ables and relative to genotypes of studied polymorphism.
Comparisons were made with the log-rank test. Death
(overall) was the primary end-point.
Statistical analyses were performed with the SPSS soft-
ware 13.0. A p value < 0.05 was considered significant.
Ethics
The investigation conforms to the principles outlined in
the Declaration of Helsinki and the study protocol was
approved by the Ethics Committee for Medical Research
on Human Beings of the Hospital das Clínicas from Uni-
versity of São Paulo Medical School. Signed informed
consent was obtained from all participants from both
samples.
Results
Genotyping the rs28362491 polymorphism
Genotype status was obtained for 493 and 916 individuals
of the HF and Control samples, respectively. All genotype
frequencies were consistent with those predicted by the
Hardy-Weinberg equilibrium. Table 1 shows allelic and
genotype frequencies among patients and controls where
ATTG1 and ATTG2 represent the allele with the deletion
and insertion, respectively. Neither the allelic, nor the
genotype frequencies revealed any difference between
patients and controls.
Clinical and demographic evaluation
We tested both patient and control samples for associa-
tion with clinical and demographic characteristics
(Tables 2 and 3, respectively). The only significant associ-
ation was observed between diabetes and the ATTG1
allele in the HF population.
Table 1: Allelic and genotype frequencies of NFKB1 -94 insertion/deletion among pacients and control.
Patients
N = 493
Controls
N = 916
p value
Genotype Frequencies
ATTG2ATTG2 0.345 0.345
ATTG2ATTG1 0.507 0.509 0.99
ATTG1ATTG1 0.148 0.146
Allelic Frequencies
ATTG2 0.59 0.575 0.93
ATTG1 0.41 0.425Santos et al. BMC Medical Genetics 2010, 11:89
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Functional Evaluation
Patients possessing the ATTG1/ATTG1  genotype pre-
sented higher right and left ventricular diameters demon-
strated by higher right ventricle (RV) diameter (P  =
0.001), left ventricle (LV) diastolic diameter (P = 0.04) and
a tendency towards higher mean LV systolic diameter (P
= 0.06). RV and LV remodeling was accompanied by
functional deterioration, as can be observed by the lower
ejection fraction (EF) in patients with the ATTG1/ATTG1
genotype (P = 0.016). Cardiac remodeling and functional
deterioration were not observed in the control popula-
tion (Table 4). However, it is interesting to note a non-sig-
nificant tendency of lower mean EF in carriers of the
ATTG1/ATTG1  genotype in control individuals (p =
0.10).
We further analyzed differences in genotype frequen-
cies between patients selected based on an EF above or
below 50%. Frequencies in patients with EF > 50% were:
40% ATTG2/ATTG2, 52% ATTG1/ATTG2  and 8%
ATTG1/ATTG1, while in patients with EF < 50% they
were: 32% ATTG2/ATTG2, 49% ATTG1/ATTG2 and 19%
ATTG1/ATTG1. Genotype ATTG1/ATTG1 was more fre-
quent in patients with EF lower than 50% (P = 0.01).
Finally, we observed that individuals who carry the
ATTG1/ATTG1  genotype presented an earlier disease
onset. Figure 1 panel A shows the Kaplan-Meier curves
for disease onset in individuals harboring the different
NFKB1  genotypes. Interesting, those who have the
ATTG1/ATTG1 genotype presented the disease, on aver-
age, 7 years sooner than those with the ATTG2/ATTG2
genotype. No significant difference was observed in
Kaplan-Meier curve for mortality (Figure 1, panel B).
Discussion
The role of NFκB in heart failure has been studied by sev-
eral authors[6] and it still remains controversial. Many
studies applied different methods to model the role of
NFkB in the heart failure scenario. These ranged from
coronary artery ligation to mouse and rat models that
block the NFKB1 gene [13-17,19]. Beyond its interaction
with other subunits, NFκB can act in the cell by two other
forms, the p105 and the homodimer (p50)2. The p105
Table 2: Demographic and clinical characteristics of the HF population according to -94 insertion/deletion genotype.
ATTG2/ATTG2 ATTG1/ATTG2 ATTG1/ATTG1 p value
Patients 170 250 73 -
Age, years 59 ± 15.2 58.2 ± 14 54.7 ± 13.7 0.09
Gender
Male n (%) 95 (56) 137 (62) 53 (59) 0.45
Ethnicity n (%)
Blacks 12 (23.5) 29 (57.0) 10 (19.5)
Mulattos 26 (38.8) 26 (38.8) 15 (22.4) 0.08
Whites 129 (35.5) 185 (51.0) 48 (13.5)
Biochemical
Serum sodium (mmol/L) 59.61 ± 1.9 59.45 ± 2.0 59.48 ± 1.7 0.72
Hemoglobin (g/dL) 13.03 ± 2.3 13 ± 2.1 13.48 ± 2 0.19
Total Cholesterol (mg/dL) 194.95 ± 50.4 185.53 ± 50.9 195.85 ± 56.6 0.17
Triglycerides (mg/dL) 123.55 ± 67.2 124.5 ± 66.4 119.15 ± 7 0.87
HDL (mg/dL) 47.22 ± 14.7 43.77 ± 15.8 45.61 ± 17.1 0.13
LDL (mg/dL) 122.74 ± 42.9 117 ± 39.5 123.7 ± 48.5 0.41
Creatinin (mg/dL) 1.36 ± 0.72 1.35 ± 0.75 1.33 ± 0.78 0.95
Diabetes n (%)
Yes 33 (35.5) 54 (54) 6 (6.5) 0.035
No 125 (34.4) 177 (49) 61 (16.6)
BMI (kg/m2) 25.36 ± 5.9 26.1 ± 5.2 24.2 ± 4.93 0.07
Heart Rate (pm) 79.3 ± 13.8 79.5 ± 12.2 80.2 ± 14.6 0.9
Diastolic Blood Pressure (mmHg) 73.9 ± 16.4 76.4 ± 18.4 78.5 ± 20.9 0.19
Systolic Blood Pressure (mmHg) 120.4 ± 30 121.5 ± 30.6 125.6 ± 31.5 0.58Santos et al. BMC Medical Genetics 2010, 11:89
http://www.biomedcentral.com/1471-2350/11/89
Page 5 of 8
forms complexes with non-NFκB family proteins provid-
ing a crosstalk between NFκB and other signaling path-
ways that regulate different cellular functions[29]. The
(p50)2, first considered a repressor of transcription, is
now believed to also act as a transcription activator. Ulti-
mately, the processing of p105 is in part dependent on the
setting of NFκB dimmers in the surroundings, differing in
each kind of cell[30]. The complex transcriptional and
post-translational modification of the NFKB1 gene and
product, respectively, might be the reason why the several
studies addressing ablation of the NFKB1 gene present
different conclusions: sometimes observing that NFκB
(p50) acts worsening HF by activation of a pro-inflamma-
tory pathway[13-16] whereas in other, protecting the
heart by activation of anti-inflammatory pathways,
matrix remodeling or attenuation of oxidative stress[19].
In the present study, we evaluated the role of a poly-
morphism that was previously described to be associated
with diminished transcription of NFKB1 due to a four
base pair deletion in the promoter region of the gene and
resulting in the loss of binding of nuclear proteins, thus,
leading to a reduced promoter activity.
The rs28362491 polymorphism was first described by
Karban et al[22] and associated to an increased risk for
ulcerative colitis. This polymorphism has been associated
with diverse human diseases but, only recently, Zhou et
al. described an association with heart disease[31]. They
observed, in 177 patients with dilated cardiomyopathy
(DCM), a higher prevalence of the genotypes ATTG2/
ATTG2 + ATTG1/ATTG2 in DCM patients, indicating
that ATTG2 carriers have increased risk of DCM. How-
ever, they only observed a non-statistical higher ATTG2
allelic frequency in DCM patients (62.7 vs. 57.1). Herein,
we used diverse HF etiologies, including DCM, and did
not observe neither genotype nor allelic distribution dif-
ferences between patients and controls (P = 0.99 and P =
0.96, respectively). This lack of association was also
observed when we compared only patients with the DCM
etiology (n = 50) with controls (P = 0.13 genotype fre-
quencies, P = 0.37 allelic frequencies, data not shown),
and, despite the low statistical power due to the small
number of patients with this specific diagnosis, we
observed that the ATTG2  allelic frequency in DCM
patients is lower than in control individuals (50% vs.
Table 3: Demographic and clinical characteristics of the Control population according to -94 insertion/deletion genotype.
ATTG2/ATTG2 ATTG1/ATTG2 ATTG1/ATTG1 p value
Number 316 466 134 -
Age, years 44.36 ± 10.46 45.01 ± 10.6 43.95 ± 10.54 0.5
Gender
Male n (%) 136 (43) 171 (36.7) 58 (43.3) 0.14
Ethnicity n (%)
Blacks 18 (31) 28 (48.3) 12 (20.7)
Mulattos 150 (33.1) 237 (52.3) 66 (14.6) 0.35
Whites 122 (38.6) 151 (47.8) 43 (13.6)
Biochemical
Hemoglobin (mg/dL) 13.83 ± 1.47 13.61 ± 1.41 13.74 ± 1.51 0.12
Total Cholesterol (mg/dL) 215.43 ± 40.73 218.52 ± 43.87 214.16 ± 49.9 0.47
Triglycerides (mg/dL) 124.07 ± 82.3 130.6 ± 92.12 139.24 ± 91.21 0.23
HDL (mg/dL) 45.46 ± 11.91 46.46 ± 12.06 44.73 ± 11.42 0.25
LDL (mg/dL) 145.59 ± 37.76 146.77 ± 39.29 142.32 ± 44.17 0.52
Creatinin (mg/dL) 0.97 ± 0.20 0.96 ± 0.02 0.98 ± 0.17 0.84
Diabetes n (%)
Yes 22 (29) 45 (58) 10 (13) 0.37
No 294 (35) 420 (50) 123 (15)
BMI (kg/m2) 26.34 ± 5.08 26.55 ± 5.08 26.47 ± 4.9 0.84
Heart Rate (pm) 70.40 ± 12.13 70.81 ± 10.46 70.73 ± 8.94 0.95
Diastolic Blood Pressure (mmHg) 83.27 ± 13.06 82.57 ± 13.45 81.73 ± 12.26 0.51
Systolic Blood Pressure (mmHg) 126 ± 20.22 128.6 ± 22.29 127.77 ± 22.45 0.25Santos et al. BMC Medical Genetics 2010, 11:89
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57.5%), indicating an opposite direction for the putative
association. These data suggest that the presence of the
ATTG2 allele itself does not represent a risk factor for
DCM or HF in general in our population.
Even considering the problems of the NFKB1 ablation
models, they are useful to point towards interesting
aspects of NFkB physiology in the heart. Recently, Tim-
mers et al[19] reported enhanced cardiac remodeling and
dysfunction in NFκB p50 knockout mice after myocardial
infarction. Knockout mice presented reduced ejection
fraction and higher LV diastolic and systolic volume, indi-
cating cardiac remodeling and deteriorated function. In
our analyses we observed a significant difference in EF,
LV diastolic and RV diameter only in HF patients (P =
0.016, P = 0.04 and P = 0.001, respectively). Signs of
impaired heart function were all associated with the
ATTG1/ATTG1  genotype. Additionally, we observed a
tendency in LV systolic diameter, LA diameter and mass
to be higher in the ATTG1/ATTG1 genotype. These data
corroborate Timmers', and is also supported by another
recent study where a model with attenuated activation of
NFκB presented similar cardiac modifications [18]. Curi-
ously, although a low EF is known to be the strongest pre-
dictor of mortality in HF, we did not observe an
association of the ATTG1  allele with survival in this
Table 4: Functional data for the HF and Control population according to -94 insertion/deletion genotype.
Patients Controls
ATTG2/ATTG2 ATTG1/ATTG2 ATTG1/ATTG1 p value ATTG2/ATTG2 ATTG1/ATTG2 ATTG1/ATTG1 p value
LAD, mm 46 ± 9.2 46.7 ± 8.8 48.9 ± 8.7 0.09 33.31 ± 3.1 33 ± 2.86 33.83 ± 3.42 0.3
AD, mm 32.8 ± 6.4 32.6 ± 5.2 32.3 ± 6.9 0.88 32 ± 2.9 31.32 ± 2.86 31.58 ± 2.74 0.18
RVD, mm 25 ± 7.73 27.07 ± 8.10 31.07 ± 7.83 0.001 16.55 ± 4.33 17.29 ± 4.77 17.27 ± 4 0.43
Left Ventricle
IS, mm 9.8 ± 2.5 9.7 ± 2.2 9.70 ± 2.1 0.81 8.98 ± 1.27 8.93 ± 1.15 8.91 ± 1.10 0.9
PWT, mm 9.6 ± 2.1 9.5 ± 1.9 9.5 ± 2 0.95 8.92 ± 1.22 8.75 ± 1.08 8.77 ± 1 0.38
DD, mm 60.8 ± 11.5 61.6 ± 11.4 65 ± 11.3 0.04 48.09 ± 4.84 48.58 ± 4.8 48.76 ± 5 0.6
SD, mm 48. ± 13.7 49.3 ± 14.3 53.5 ± 15.1 0.06 28.7 ± 3.74 29.26 ± 4.10 29.74 ± 4.82 0.24
EF, (%) 47.9 ± 18.5 45.6 ± 19 39.5 ± 18.2 0.016 71.63 ± 4.77 71 ± 5.2 69.70 ± 6.85 0.1
Mass, g 247 ± 104 249 ± 89 267 ± 88 0.36 151 ± 47.87 151 ± 42.7 152 ± 46.9 0.99
LAD - Left Atrium Diameter, AD - Aortic Diameter, RVD - Right Ventricle Diameter, IS - Intraventricular Septum, PWT - Posterior Wall Thickness, DD 
- Diastolic Diameter, SD - Systolic Diameter, EF - Ejection Fraction
Figure 1 A Kaplan-Meier curve for Disease Onset (A) and Mortality (B). Blue line represents genotype ATTG1/ATGG1, Green line genotype ATTG1/
ATTG2 and black line genotype ATTG2/ATTG2. In B, the different forms represent the event death for each genotype.Santos et al. BMC Medical Genetics 2010, 11:89
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patient cohort (P = 0.8) (Figure 1, panel B). Interestingly,
the same was observed in p50 KO mice and in mice with
attenuated expression of the NFKB1 gene[18,20]. Never-
theless, we demonstrated that carriers of the ATTG1/
ATTG1 genotype exhibit a significant anticipated disease
onset (of nearly 7 years). Taken together, these data sug-
gest that the presence of ATTG1/ATTG1  genotype is
involved with an enhanced cardiac remodeling process
and impaired heart function. The implications of this
association to long term prognosis remain to be explored.
The main limitation herein is the lack of replication of
the significant associations in another equivalent, inde-
pendent cohort. This, beyond the confirmation of data,
would also give other important information regarding
survival and may shed light into why we were not able to
observe the expected higher mortality in patients with
the ATTG1/ATTG1 genotype.
Conclusion
There is no genotype or allelic association between the
studied polymorphism and the development of HF. How-
ever, our data suggest that a diminished activation of
NFKB1, previously associated with the ATTG1/ATTG1
genotype, may act modulating the onset of disease and,
once the individual has HF, the genotype may modulate
disease severity by increasing cardiac remodeling and
function deterioration.
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